Beyond the standard liver-targeted outcomes such as steatosis, transaminase and fibrosis rates, trials should also include assessment of improvements in insulin resistance, dyslipidemia, blood pressure management and cardiovascular risk. The gene discussed is INS; the disease is steatosis.